Evaluation of the evolution of the operative technique in patients submitted to nephroureterectomy for urothelial tumor in a reference hospital.

• Grant number: 23/11038-0
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: October 01, 2023
• End date: September 30, 2024
• Field of knowledge: Health Sciences - Medicine - Surgery
• Principal Investigator: Fabiana de Lima Vazquez
• Grantee: Vitor Antonio Fragoso Pacheco
• Host Institution: Hospital do Câncer de Barretos. Fundação Pio XII (FP). Barretos , SP, Brazil

Abstract

Upper urinary tract carcinoma is a malignancy of urothelial cells that line the urinary tract, and can affect the renal calyces, renal pelvis, ureter or ureteral meatus. In Western countries, the annual incidence is two new cases per 100,000 inhabitants, and currently there is much controversy regarding the choice of surgical treatment for patients diagnosed with this type of cancer. Understanding the postoperative clinical prognosis of treated patients helps to understand and standardize the choice of appropriate techniques and approaches, thereby improving patient survival. OBJECTIVE: To analyze the oncological and postoperative prognosis of patients diagnosed with urothelial carcinoma of the upper urinary tract in a specialized oncology institution that implemented a change in the surgical treatment of the disease, predominantly shifting from open surgery to minimally invasive approaches over time. MATERIALS AND METHODS: A retrospective cohort study will be conducted, with the study factor being the clinical and surgical prognosis of urothelial carcinoma of the upper urinary tract. Patients meeting the following criteria will be included in the study: diagnosed with urothelial carcinoma of the upper urinary tract; treated at the Hospital de Amor de Barretos between 2000 and 2020; with a pielocaliceal or any ureteral segment location; with localized (cT1) or locally advanced (ecT2) disease; with clinically positive lymph nodes or not (cN0, N1, or N2); with any form of resection (endoscopic, trans or extravesical, open or minimally invasive approach). Patients with metastatic disease at diagnosis (cM1) will be excluded.